Clinical Studies

Our practice participates in national research studies that focus on advanced study in heart disease.

If you are interested in enrolling in one of our active research studies below, call your local office for an appointment to determine your eligibility.

Current Studies

CIRT (Cardiovascular Inflammation Reduction Trial)

Sponsor - National Heart Lung and Blood Institute (NHLBI)
PI - Dr. Ashish Agarwal

The purpose of CIRT is to directly test the inflammatory hypothesis of atherosclerosis to determine whether treatment with low dose methotrexate (LDM) will reduce the rate of myocardial infarction, stroke, or cardiovascular death among patients with atherosclerosis.

UPGRADE (Utility of PharmacoGenomics for Reducing Adverse Drug Effects)

Sponsor - Companion Dx Reference Labs, LLC
PI - Dr. Richard Hyman

The purpose of UPGRADE is to track and analyze the clinical utility of pharmacogenomics testing (PGx) for the management of pharmacotherapy. The primary metric will be the tabulation of the frequency of meaningful changes in a subjects medication regimen after pharmacogenomics testing.

Previous Studies


The purpose of IMPACT is to study whether early awareness of an abnormal heart rhythm, detected by Home Monitoring®, in combination with blood thinning medication is able to reduce the risk of stroke and blood clots. Additionally, safe and early stop of blood thinners will be assessed to see if bleeding can be reduced.

Click here to read the study documentation.


The purpose of this study is to find out if tadalafil can safely reduce the need for hospital admissions and improve survival in patients who have both heart failure and high blood pressure in the vessels that carry blood to the lungs. Heart failure is a weakening of heart muscle which causes symptoms of fatigue and difficulty breathing. Although treatments for heart failure exist, additional treatments are needed to improve symptoms and health outcomes in patients with heart failure.

Click here to read the study documentation.

ROADMAP: Advancing the Treatment of Ambulatory Heart Failure Patients

PI - Dr. Jerome Thomas

ROADMAP a study for patients with heart failure. It compares the effectiveness of heart failure treatment using either (a) standard heart failure medications and treatments versus (b) standard heart failure medications and treatments plus HeartMate II (HMII) Left Ventricular Assist Device (LVAD). The HMII LVAD is FDA approved for heart failure patients. Patients receiving the HMII LVAD will continue to receive medications and other heart failure treatments.

Click here to read the study documentation.

UPGRADE Registry

Sponsor - Companion Dx Reference Labs, LLC
PI - Dr. William Hirsch

Pharmacogenomics is the study of genetics and how it affects the way you respond to drugs. Your genetics determine your individual characteristics and the way you may react to medications. The UPGRADE Registry is a research study to collect data to see if the use of pharmacogenomic (PGx) test data will help to better manage the medications that you are on.

Share Button